| Literature DB >> 27050509 |
Tania Løve Aaes1, Agnieszka Kaczmarek1, Tinneke Delvaeye2, Bram De Craene3, Stefaan De Koker4, Liesbeth Heyndrickx1, Iris Delrue1, Joachim Taminau3, Bartosz Wiernicki1, Philippe De Groote1, Abhishek D Garg5, Luc Leybaert6, Johan Grooten4, Mathieu J M Bertrand1, Patrizia Agostinis5, Geert Berx3, Wim Declercq1, Peter Vandenabeele7, Dmitri V Krysko1.
Abstract
Successful immunogenic apoptosis in experimental cancer therapy depends on the induction of strong host anti-tumor responses. Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death. We have developed a genetic model in which direct dimerization of FADD combined with inducible expression of RIPK3 promotes necroptosis. We report that necroptotic cancer cells release damage-associated molecular patterns and promote maturation of dendritic cells, the cross-priming of cytotoxic T cells, and the production of IFN-γ in response to tumor antigen stimulation. Using both FADD-dependent and FADD-independent RIPK3 induction systems, we demonstrate the efficient vaccination potential of immunogenic necroptotic cells. Our study broadens the current concept of immunogenic cell death and opens doors for the development of new strategies in cancer therapy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27050509 DOI: 10.1016/j.celrep.2016.03.037
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423